Company: MDCXW
Filing Date: 2025-07-03
Form Type: 8-K/A
Source: 0001062993-25-012533
Chunk: 1

Company: Medicus Pharma Ltd.
Filing Date: 2025-07-03
Form: 8-K/A
Chunk 1
---
.12b -2 of this chapter). Emerging growth company ☑ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Explanatory Note This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Medicus Pharma Ltd. (the "Company") on June 30, 2025 (the "Original Form 8-K") to (1) as previously indicated in the Original Form 8-K, file as Exhibit 2.1 to this Current Report on Form 8-K/A that certain securities exchange agreement among the Company, Antev Limited ("Antev") and certain securityholders of Antev, dated as of June 29, 2025 (the "Agreement"), and (2) to incorporate the Agreement by reference herein. Other than as set forth in this Explanatory Note, this amendment does not amend any other disclosures in the Original Form 8-K. Item 9.01. Financial Statements and Exhibits. (d) Exhibits.

| Exhibit 
 No.     
 2.1*#   
 99.1    |     | Description                                                                                                                                                      
 Share Exchange Agreement, dated June 29, 2025, by and between Medicus Pharma Ltd., Antev Limited and each of the securityholders of Antev Limited party thereto. 
 Press Release, dated June 30, 2025 (incorporated by reference to Exhibit 99.1 of the Original Form 8-K).                                                         |
|:--------|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the inline XBRL document).                                                                                     |

| * |     | Certain portions of this exhibit have been redacted pursuant to Item 601(b)(2)(ii) of Regulation S-K. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request. |
| 

# |     | Certain schedules and exhibits have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.                    |
Forward Looking Statements Certain information in this Current Report on Form 8-K constitutes "forward-looking information" under applicable securities laws. "Forward-looking information